
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd Inc. is positioned favorably within the clinical-stage biopharmaceutical sector, developing innovative antibody-based therapies aimed at combating infectious diseases, particularly with a focus on COVID-19. The company's lead candidates, ADG20 and VYD222, utilize cutting-edge technologies that enhance their antiviral potency and longevity, with VBY329 demonstrating significant improvements in neutralization against resistant variants compared to existing treatments. Coupled with a robust market potential projected to expand to $3-4 billion globally by 2030 and supportive Phase 1/2 safety data, these factors contribute to a positive outlook on Invivyd's stock trajectory.
Bears say
Invivyd Inc operates in the competitive clinical-stage biopharmaceutical sector, focusing on antibody-based therapies aimed at infectious diseases. Despite a substantial total addressable market of approximately $4 billion for COVID-19 vaccines in 2024, challenges arise from the limitations of existing vaccines highlighted by management, including waning antibody responses and public hesitancy. The company's reliance on engineered immunity as a solution may face skepticism, pointing to risks in achieving widespread adoption and commercial viability, contributing to a negative outlook on its stock.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares